0 Replies
PASADENA, Calif. - July 11, 2012 - Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide®, a new class of treatment for obesity. Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - June 26, 2012 - Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced the publication of data demonstrating that its anti-obesity drug candidate, Adipotide, induces rapid metabolic changes with implications for Type II diabetes. Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - June 6, 2012 - Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical candidate. Contine Reading & Discuss→
0 Replies
PASADENA, California, May 22, 2012 - Arrowhead Research Corporation (NASDAQ:ARWR) today announced that Darren Wakefield, Ph.D., one of its Senior Scientists at its Madison, WI research and development facility presented data at the TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Conference in Las Vegas, NV. Contine Reading & Discuss→
0 Replies
PASADENA, California, May [9], 2012 - Arrowhead Research Corporation (NASDAQ:ARWR) today announced that David Lewis, Ph.D., Vice President Biology and Site Head of its Madison, WI research and development facility presented data at the European Foundation for Clinical Medicine Conference in Basel, Switzerland. Contine Reading & Discuss→
0 Replies
PASADENA, California, May 8, 2012 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended March 31, 2012. Contine Reading & Discuss→
0 Replies
PASADENA, California, May 3, 2012 - Arrowhead Research Corporation (NASDAQ:ARWR) today announced that senior management will present data for its Dynamic PolyConjugateTM (DPC) delivery platform for siRNA delivery including its RNAi therapeutic candidate for the treatment of hepatitis B virus (HBV) at several upcoming scientific conferences. Contine Reading & Discuss→
0 Replies
PASADENA, California, May 1, 2012 - Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 second quarter ended March 31, 2012, on Tuesday, May 8, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - April 11, 2012 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced that it has acquired Alvos Therapeutics, Inc. (formerly known as Mercator Therapeutics, Inc.), a privately-held company that licensed a large platform of proprietary human-derived homing... Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - March 7, 2012 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that it has released a white paper describing the health problem posed by the hepatitis B virus (HBV), the substantial unmet need for chronic HBV... Contine Reading & Discuss→
